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Abstract: In recent years, the importance of vitamin A in adipose tissue biology, obesity 
and type II diabetes has become apparent. This review focuses on recent developments 
within the area of vitamin A and adipose tissue biology. Adipose tissue has an active 
vitamin A metabolism as it not only stores vitamin A but retinol is also converted to its 
active  metabolite  retinoic  acid.  Several  mouse  models  point  to  a  relationship  between 
vitamin A metabolism and the development of adiposity. Similarly, in vitro studies provide 
new molecular mechanisms for the function of different forms of vitamin A and retinol- or 
retinoic acid-binding proteins in adipose tissue.  




Vitamin A must be obtained from the diet by intake of either food containing preformed vitamin A 
(e.g., red meats) or provitamin A carotenoids (e.g., carrots, green leafy vegetables). Most actions of 
retinol are mediated by its metabolite retinoic acid, which is synthesized intracelluarly in target tissue 
from retinol [1]. In the first step, retinol is reversibly oxidized to retinaldehyde. Two major enzyme 
classes, cytosolic aldehyde dehydrogenases (ADHs) and microsomal short-chain dehydrogenases (SDR) 
have  been  proposed  to  catalyze  this  reversible  reaction  [2,3].  In  the  second  step,  retinaldehyde  
is  irreversibly  oxidized  to  retinoic  acid.  The  enzyme  class  of  cytosolic  retinaldehyde 
dehydrogenases (RALDH) has been clearly identified to catalyze this step [4].  
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Retinoic acid exerts its pleiotropic effects mostly by controlling the expression of over 500 genes 
through binding to and activating retinoic acid receptors (RAR) and retinoid X receptors (RXR), both 
of which are members of the nuclear hormone receptor family [5,6]. In addition to its oxidation to 
retinoic acid, retinol can be esterified and stored as retinyl ester in hepatic stellate cells or, to a smaller 
extent, in extrahepatic tissues including adipose tissue (see below).  
The liver plays a central role in vitamin A physiology. Postprandially, vitamin A is delivered to the 
liver as a constituent of chylomicron remnants. In the liver, retinol is re-esterified to retinyl ester by 
lecithin:retinol acyltransfrase (LRAT) and stored in hepatic stellate cells, the major storage site for 
vitamin A in the body [7]. Retinol bound to retinol-binding protein (RBP; RBP4) is secreted from the 
liver  to  maintain  serum  vitamin  A  levels  and  to  deliver  retinol  to  extrahepatic  target  tissues  for 
intracellular retinoic acid synthesis [8]. RBP contains one binding site for retinol and in plasma RBP 
circulates  as  a  1:1  complex  with  transthyretin.  Plasma  RBP-retinol  levels  are  under  homeostatic 
regulation and are maintained at levels between 2 and 3 M [8].  
Vitamin  A,  its  metabolites,  and  its  synthetic  analogs  are  collectively  known  as  retinoids.  The 
importance  and  essentiality  of  retinoids  to  human  health,  facilitating  normal  vision,  reproduction, 
immune function, and cell differentiation have been widely shown and established [9]. In recent years, 
the  importance  of  retinoids  in  adipose  tissue  biology,  obesity  and  type  II  diabetes  has  become 
apparent. This review will focus on recent new developments within the area of retinoids and adipose 
tissue biology.  
2. Adipose Tissue 
2.1. General  
White adipose tissue is the major tissue for storage of excessive energy in the form of triglycerides, 
releasing fatty acids into the circulation in times of fasting and starvation. In addition to being an 
energy reserve for fatty acids, adipose tissue is also an active endocrine organ secreting many different 
substances,  including  adipokines  with  paracrine  or  endocrine  function  [10–12].  It  has  become 
increasingly clear that adipose tissue is an essential regulator of whole-body energy homeostasis [13]. 
In light of increased rates of obesity in countries worldwide, and the consequent increase in associated 
morbidity,  understanding  adipose  tissue  development  and  physiology  has  become  of  increasing 
importance. Below we highlight the role of retinoid metabolism in this context. 
2.2. Retinoid Metabolism in Adipose Tissue 
Retinoids  in  adipose  tissue  are  derived  from  several  sources.  Retinol  bound  to  retinol-binding 
protein  in  the  circulation  is  one  source  used  by  adipose  tissue.  Furthermore,  retinyl  ester  and  
-carotene present in chylomicrons postprandially reach adipose tissue. Lipoprotein lipase present on 
endothelial  cells  facilitates  the  uptake  of  these  postprandial  retinoids  into  adipose  tissue  [14].  
The presence of -carotene monoxygenase type 1 (Bcmo1) in adipose tissue enables the conversion of 
-carotene to retinaldehyde [15,16]. Nutrients 2011, 3  
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It has been estimated that adipose tissue stores 10–20% of total retinoids in the body as retinyl 
esters [17]. Under conditions of dietary vitamin A deficiency, the adipose retinol/retinyl ester stores 
are readily mobilized as evidenced by decreasing levels [18–20].  
Mice deficient in lecithin:retinol acyltransfrase (LRAT), the enzyme that catalyzes the esterification 
of retinol, have very low hepatic retinyl ester stores, but adipose retinyl ester levels in these mice is 
higher than in wild-type mice. This indicates that adipose tissue can store retinol as retinyl esters when 
hepatic  retinol  storage  is  defective.  These  data  also  indicate  that  LRAT  is  the  dominant  enzyme  
for  hepatic  retinol  esterification  but  in  adipose  tissue  a  different  enzyme,  and  a  yet  unidentified  
acyl-CoA:retinol  transferase  (ARAT),  may  be  important  for  retinol  esterification  [21,22]. 
Diacylglycerol acyltransferase type 1 (DGAT1) has been proposed to be this ARAT [23,24] however, 
in mice lacking both DGAT1 and LRAT, adipose retinyl ester levels were not significantly different 
from those in control mice [25], suggesting the possible existence of an additional enzyme involved  
in esterifying retinol.  
In addition to esterification, retinol is converted to retinaldehyde and retinoic acid in adipose tissue. 
Both, aldehyde dehydrogenase (ADH1), catalyzing the first step in retinol oxidation and retinaldehyde 
dehydrogenase  (Raldh1),  responsible  for  retinoic  acid  synthesis,  have  been  identified  in  adipose  
tissue [26]. The role of the latter as it may relate to adipocyte differentiation is discussed below [26].  
Intracellularly, protein binding may be an important mechanism to direct retinol towards enzymes 
that metabolize retinol to retinaldehyde and then to retinoic acid or retinyl esters; this would protect 
retinol  from  nonspecific  oxidation/isomerization  [27–29].  These  roles  have  been  attributed  to 
intracellular proteins that specifically bind retinol; they are known as cellular retinol-binding proteins 
(CRBP)  [27,29,30].  Thus  far,  three  types,  CRBP-I,  CRBP-II  and  CRBP-III,  have  been  described  
in  murine  tissues  [27,31,32].  Together  with  cellular  retinoic  acid-binding  proteins  (CRABP)  and  
fatty  acid-binding  proteins  (FABP),  they  belong  to  the  family  of  intracellular  lipid-binding  
proteins  (iLBP)  [30].  It  is  currently thought that the primary role of  CRBP-I and  CRBP-III  is  to 
facilitate  the  esterification  of  retinol  to  retinyl  ester  catalyzed  by  lecithin:retinol  acyltransferase 
(LRAT) [31,33]. The lack of CRBP-I in a mouse model leads to a 50% reduction of vitamin A storage 
in the liver and higher hepatic turnover of vitamin A in mice [33,34]. Similarly, we have shown that 
the absence of CRBP-III leads to decreased retinol esterification during lactation resulting in decreased 
milk retinyl ester levels in mice [31]. 
CRBP-I and CRBP-III have high protein homology but they differ in their affinity for retinol and in 
their tissue and cellular expression patterns [31,32,35]. CRBP-I binding affinity for retinol is almost 
two orders of magnitude greater than that of CRBP-III. Both binding proteins are expressed in adipose 
tissue,  with  CRBP-I  expression  restricted  to  preadipocytes  and  CRBP-III  expression  localized  to 
endothelial  cells  and  mature  adipocytes  [31,32,35].  This  localization  suggests  that  they  may  have 
different functions and this possibility is discussed below in more detail.  
In addition to CRBP, other members of the intracellular retinoid-binding protein family, cellular 
retinoic acid-binding proteins (CRABP), which bind retinoic acid with high affinity, are also expressed 
in adipose tissue and are involved in delivering RA into the nucleus. Of particular interest is CRABP-II 
as it has recently been shown to be involved in controlling adipogenesis (see below).  
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3. Results from Dietary Interventions in Rodents and Knockout Mice 
3.1. Retinoid Supplementation and Body Weight  
While the association between dietary vitamin A intake and obesity in humans is difficult to assess, 
several studies employing rodent models have examined this relationship with various outcomes [36–41]. 
Supplementation of obese rats with high levels of dietary vitamin A (129 mg of vitamin A/kg) led to 
significant  weight  loss  compared  to  a  control  group  receiving  lower  levels  of  dietary  vitamin  A  
(2.6 mg of vitamin A/kg) [36]. A similar supplementation regimen in lean mice had no effect [37]. 
In contrast, short-term supplementation with retinoic acid resulted in weight loss, decreased adiposity 
and increased insulin sensitivity in several lean and/or obese mouse models [37–41]. Similarly, a diet 
deficient in vitamin A (no detectable vitamin A levels) led to an increase in adiposity in mice [40]. 
3.2. Several Knock-Out Models Allow Insights in Retinoid Metabolism in Adipose Tissue 
3.2.1. Retinol Dehydrogenase Type 1 (RDH1)  
Apart from dietary studies, studies of genetically engineered mice provide further insights into the 
role of retinoid metabolism in adipose tissue biology and energy metabolism. Several mouse models 
underscore the role of intracellular retinaldehyde and/or retinoic acid synthesis in the development of 
adiposity. Napoli and coworkers have shown that retinol dehydrogenase (RDH1), which catalyzes the 
first  reversible  oxidation  of  retinol,  is  important  during  conditions  of  marginal  intake  of 
vitamin A [42]. In mouse models lacking RDH1, both retinol and retinyl ester levels were significantly 
increased during low dietary vitamin A intake (<4 IU/g) but not under conditions of excess vitamin A 
intake  (>15  IU/g)  [42].  Intracellular  retinoic  acid  levels  remained  unchanged.  Interestingly,  a 
significant increase in body weight on a vitamin A restricted diet occurred in RDH1 knockout mice 
compared to wild-type mice [43]. The weight gain was mostly due to increased fat mass, but molecular 
mechanisms remain to be determined, especially as RDH1 is predominantly expressed in the liver but 
not adipose tissue.  
3.2.2. Retinaldehyde Dehydrogenase Type I (Raldh1)  
Further  evidence  that  intracellular  retinoid  metabolism  affects  both  adiposity  and  glucose 
homeostasis comes from a mouse model deficient in retinaldehyde dehydrogenase, type 1 (Raldh1), an 
enzyme responsible for the oxidation of retinaldehyde to retinoic acid. The absence of Raldh1 led to a 
significant  increase  in  retinol  and  retinaldehyde  levels  in  adipose  tissue.  Metabolically  Raldh1 
knockout mice had altered adipogenesis and glucose homeostasis. Specifically, when fed a high-fat 
diet, Raldh1 knockout mice remained leaner, and more insulin sensitive and glucose tolerant, than 
control mice [26].  
3.2.3. Beta-Carotene Monoxygenase (Bcmo1)  
Like preformed retinol, -carotene is a precursor for the synthesis of retinaldehyde and retinoic  
acid [44,45]. -carotene presents a precursor as it can be enzymatically cleaved resulting into the Nutrients 2011, 3  
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formation  of  one  or  two  retinaldehyde  molecules.  The  latter  can  subsequently  be  reduced  to 
obtain retinol. 
The enzyme -carotene monoxygenase type I (Bcmo1), present in intestine, testes and adipose 
tissue,  can  convert  -carotene  into  retinaldehyde  via  central  cleavage  of  -carotene.  The  lack  of 
Bcmo1  in  a  murine  model  affected  vitamin  A  homeostasis  as  well  as  lipid  and  adipose  tissue 
metabolism. Mice deficient in Bcmo1 developed dyslipidemia and hepatic steatosis [15]. In mice with 
diet-induced  obesity,  the  lack  of  Bcmo1  was  associated  with  a  significant  increase  in  adiposity, 
elevated serum free fatty acid levels and fatty liver compared to wild-type mice [15]. 
3.2.4. Cellular Retinol-Binding Protein Types I and III (CRBP-I&III)  
As described above, both CRBP-I and CRBP-III are expressed in adipose tissue but in different 
cellular compartments [32,46,47]. We have recently reported that both CRBP-I and CRBP-III play 
important roles in adipose tissue biology and energy homeostasis [46,47]. The absence of CRBP-III 
did not result in changes of intracellular retinoid levels in adipose tissue. However, when fed a high-fat 
diet,  mice  lacking  CRBP-III  showed  significantly  decreased  adiposity  and  developed  less  hepatic 
steatosis, as evidenced by decreased liver triglyceride levels, as compared to control mice [47]. Lower 
serum fatty acid levels in CRBP-III knockout mice may offer an explanation for lower hepatic TG 
accumulation [47].  
This is contrasted by results from mice lacking CRBP-I. A high-fat diet resulted in a significant increase 
in adiposity in CRBP-I knockout mice compared to wild-type mice [46]. However, CRBP-knockout 
mice remained insulin sensitive and glucose tolerant despite diet-induced obesity. The positive impact 
of adipose tissue expansion in the absence of CRBP-I mice may be explained by increased PPAR 
expression, an increased frequency of small adipocytes, and higher serum adiponectin levels compared 
to control mice [46]. 
3.2.5. Retinol-Binding Protein (RBP/RBP4)  
In addition to the role of intracellular retinoid metabolism in energy homeostasis, it has also been 
suggested that retinol-binding protein (RBP/RBP4) synthesized and secreted from adipose tissue—not 
hepatic  RBP4—may  act  as  an  adipokine  that  negatively  affects  blood  glucose  homeostasis  in  
mice  [17,48].  Accordingly,  mice  deficient  in  RBP/RBP4  remained  more  insulin  sensitive  under 
conditions  of  diet-induced obesity [48]. Yang and Graham [48] showed a  strong positive relation 
between increased serum RBP4 levels and the incidence of type II diabetes and insulin resistance. 
Their results were based on findings in mice lacking the glucose transporter 4 (GLUT4) specifically in 
adipose tissue (GLUT4 KO) rendering the mice insulin resistant. Interestingly, the lack of adipose 
tissue GLUT4 was associated with increased expression of RBP4 in adipose tissue but not in liver 
resulting in increased serum RBP4 levels in the GLUT4 KO mouse model. Consistent with these data, 
mice deficient in RBP4 remained more insulin sensitive under conditions of diet-induced obesity [48]. 
Therefore  it  has  been  speculated  that  adipocyte  derived  RBP4—not  hepatic  RBP4—may  be  an 
adipokine and contribute to the development insulin resistance [48]. The molecular mechanisms are 
unclear. Chronic RBP4 elevation may lead to increased hepatic glucose production through stimuating 
the  hepatic  enzyme  phosphoenolpyruvate  carboxykinase  and  downregulating  insulin  signalling  in  Nutrients 2011, 3  
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the muscle. In addition, it was suggested that RBP4 may inhibit the phosphorylation of the insulin 
receptor  [49].  To  date  the  results  are  still  conflicting  in  humans  as  some  studies  confirmed  this 
relationship [50–53] while others did not [49,54–59]. 
4. Molecular Mechanism for Retinoid Action in Adipose Tissue 
The question that arises is what are the potential mechanisms of action by which retinoids and 
retinoid binding proteins affect adipose tissue biology and/or energy metabolism? Adipogenesis is 
governed by a complex regulatory cascade that has been extensively studied in committed clonal cell 
lines  including  3T3-L1  cells  (reviewed  in  [60,61]).  In  general  terms,  it  involves  the  induction  of 
members of the CCAAT/enhancer binding protein family (C/EBP) and PPAR. Early in adipogenesis, 
C/EBP expression is induced, followed by the induction of PPAR and C/EBP expression. Both 
PPAR and CEBP lead to activation or enhanced expression of adipocyte markers [61]. PPAR is 
considered the master regulator of adipogenesis and in its absence adipocyte differentiation cannot 
proceed [60]. Table 1 provides a summary of retinoid action described in the following sections.  
Table 1. Retinoid action in adipocyte differentiation (details see text).  
Protein  Action in adipocyte differentiation 
Retinol-binding protein 
(RBP/RBP4)  
Increased expression in adipocytes is associated with increased 
systemic insulin resistance [48] 
Retinaldehyde 
Dehydrogenase, type I 
(RALDH1)  
Present in mature adipocytes it is involved in maintaining adipocyte 
differentiation. Lack of Raldh1 results in lack of adipocyte 
formation through modulating PPAR and RXR action [26] 
Cellular-retinol binding 
protein, type I (CRBP-I) 
Present in preadipocytes it is involved in inhibiting preadipocyte 
differentiation. Lack of CRBP-I leads to enhanced adipocyte 
differentiation and increased PPAR activity [46] 
Cellular-retinol binding 
protein, type III (CRBP-III) 
Present in adipocytes supports differentiation of adipocytes. Lack 
of CRBP-III leads to decreased adipose tissue development and 
decreased PPAR activity [47] 
Cellular-retinoic acid binding 
protein, type II (CRABP-II) 
Present in preadipocytes and is important in retinoic acid mediated 
inhibition of preadipocyte differentiation via RARs [62] 
Beta-carotene monoxygenase 
(BCMO) 
Present in adipocytes and it facilitates retinoic acid generation from 
-carotene. Lack of BCMO activity leads to increased adipocyte 
differentiation and increased PPAR expression [16] 
4.1. Retinoic Acid, -carotene and the Repression of Adipogenesis  
It  has long been  appreciated that all-trans-retinoic acid can inhibit adipocyte  differentiation by 
binding  to  and  activating  retinoic  acid  receptor  (RAR)  [63–65].  All-trans-retinoic  acid  inhibits 
adipogenesis early in the differentiation process by blocking the transcriptional activity of C/EBP [66]. 
Suppressed  C/EBP  activity  lowers  the  expression  of  PPAR,  thus  decreasing  adipogenesis.  In 
addition,  retinoic  acid  may  affect  the  cell  cycle,  keeping  cells  in  a  proliferative  state  rather  than 
allowing  growth  arrest,  which  is  essential  for  adipogenesis  [67].  Retinoic  acid  no  longer  has  an Nutrients 2011, 3  
 
33 
inhibitory effect on adipocyte differentiation if added to the cell culture after early differentiation is 
completed [16,68].  
Retinoic acid applied to mature adipocytes appears to induce lipolysis and influence the production 
of several adipokines that are secreted into the tissue culture media. However, -carotene and the 
subsequent  intracellular  generation  of  retinoic  acid  decreased  adipocyte  differentiation  after  early 
differentiation  providing  mechanistic  data  for  the  increased  adiposity  observed  in  mice  lacking  
Bcmo1 [15]. The addition of -carotene to 3T3-L1 cells during the mid stage of differentiation (day 5) 
results in a repression of adipocyte differentiation and loss of lipids [16]. Inhibition of the activity of 
Bcmo1 abolishes this effect. Interestingly, the gene for Bcmo1, which is a PPAR target gene, is 
highly expressed in mature adipocytes, allowing for -carotene to be converted to retinoic acid. The 
addition of -carotene, however, leads to repression of PPAR expression in the cell model, through a 
mechanism has not yet been identified.  
This differential effect of retinoic action on adipocyte differentiation, i.e., that retinoic acid has an 
inhibitory role at early but not at later stages of the differentiation process may be explained by the fact 
that retinoic acid can be transported to the nucleus via two binding proteins, namely CRABP-II or 
FABP5  [38].  CRABP-II  will  deliver  retinoic  acid  for  binding  to  RAR  while  FABP5  will  deliver 
retinoic acid to PPAR/. Thus, in cells that express high levels of CRABP-II, retinoic acid will 
activate RAR and, conversely, in cells high in FABP5 will activate PPAR/ and their respective 
downstream pathways [38]. Recently, Berry et al. [62] provided data indicating that CRABP-II is 
highly expressed during early adipocyte differentiation but its expression is repressed during later 
stages.  The  lack  of  CRABP-II  after  early  differentiation  may  thus  explain  that  retinoic  acid  only 
inhibits differentiation early but not in later stages of differentiation.  
4.2. Effect of Retinaldehyde on Adipogenesis  
Similar to retinoic acid, retinaldehyde is also capable of inhibiting adipogenesis in vitro and in vivo. 
As shown above (section 3.2.2), in the absence of Raldh1, increased intracellular retinaldehyde levels 
are accompanied by the development of decreased adiposity [26]. In contrast to the effect of retinoic 
acid on adipogenesis, the effect of retinaldehyde on adipogenesis might be due to the repression of 
PPAR activity [26] pointing to retinaldehyde as a transcriptional regulator. Retinaldehyde appears to 
be able to bind both PPAR and RXR resulting in a repression of receptor activation and thus offering 
an explanation for retinaldehyde mediated inhibition of adipocyte differentiation.  
4.3. CRBP-I and CRBP-III Have Opposing Effects on Adipogenesis  
We have recently shown that CRBPs are important participants in adipogenesis. Both CRBP-I and 
CRBP-III  are  expressed in adipose tissue with CRBP-I  present in preadipocytes and CRBP-III  in 
adipocytes. We have identified CRBP-III to be a PPAR target gene and thus examined whether it 
participates in adipogenesis [47]. Using the 3T3-L1 cell model we showed that CRBP-III is expressed 
during mid- and late-stage differentiation [47]. To test the role of CBRP-III in vivo we used our  
CRBP-III  knockout  mouse  model.  When  fed  a  high-fat  diet,  mice  lacking  CRBP-III  developed 
decreased adiposity. Based on our in vitro data, it appears that lack of CRBP-III, PPAR is markedly 
downregulated indicating that CRBP-III is important in maintaining adipogenesis (unpublished). In Nutrients 2011, 3  
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contrast, our data indicate that CRBP-I is an important inhibitor of adipogenesis [46]. Lack of CRBP-I 
in vivo led to increased adiposity. Similarly, in vitro silencing of CRBP-I led to enhanced adipocyte 
differentiation in 3T3-L1 preadipocyte cells and mouse embryonic fibroblasts (MEF). In addition, 
although  CRBP-I  is  specifically  expressed  in  preadipocytes  it  does  not  appear  to  regulate  known 
inhibitory genes of adipogenesis. Our data point to a role of CRBP-I affecting PPAR function. Further 
examination of molecular markers revealed that the expression and activity of PPAR but not of other 
transcriptional  regulators  important  during  the  different  stages  of  differentiation  were  specifically 
increased in the absence of CRBP-I in vitro and in vivo. Interestingly, retinoid homeostasis was not 
altered in cells lacking CRBP-I. This finding is very similar to data presented on the enzyme retinol 
saturase  (RetSat),  where  the  function  of  RetSat  in  adipocytes  was  not  readily  explained  by  its 
enzymatic  role  of  generating  13,14-dihydroretinol  from  retinol  [69].  Taken  together  CRBP-I  and 
CRBP-III  appear  to  play  important  opposing  roles  in  adipogenesis  with  CRBP-I  repressing  and  
CRBP-III maintaining adipogenesis. 
5. Summary 
In summary, retinoid metabolism is intricately involved in adipose tissue biology and thus affects 
whole body glucose and lipid homeostasis. Dietary studies and genetically engineered mouse models 
provide  valuable  insights  into  the  roles  of  retinoid  metabolism  in  adipose  tissue  biology.  Several 
mouse models with disruption in different parts of retinoid metabolism provide evidence for a role of 
retinoid in adipose tissue biology and energy homeostasis. On a molecular level it has long been 
appreciated  that  retinoic  acid  can  inhibit  adipogenesis.  However,  in  recent  years  new  research  
has  emerged  pointing  to  new  molecular  pathways  for  retinoid  functioning.  Results  from  these  
studies  suggest  that  alterations  of  retinoid  metabolism  affect  the  activity  of  the  master  regulator  
PPAR  [16,26,46,47,69].  The  specific  mechanisms  remain  to  be  studied.  Ongoing  studies  will  
offer new insights into adipose physiology and the mechanisms for the regulation by retinoids of 
glucose  and  lipid  metabolism.  These  studies  will  contribute  to  further  understanding  the  factors 
important to adipose tissue development and may lead to future therapeutic interventions. These may 
include the development of small molecules that directly target adipose tissue development.  
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